Fostamatinib is a prescription medicine indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. It is available as tablets for oral use. MedsAcross supplies Fostamatinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Source: US FDA prescribing information
Fostamatinib is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK). The major metabolite of fostamatinib, R406, inhibits signal transduction of Fc-activating receptors and B-cell receptor. The fostamatinib metabolite R406 reduces antibody-mediated destruction of platelets.
Source: US FDA prescribing information
Initiate TAVALISSE at 100 mg orally twice daily with or without food. After 4 weeks, increase to 150 mg twice daily, if needed, to achieve platelet counts of at least 50 × 10 9 /L as necessary to reduce the risk of bleeding. Manage adverse reactions using dose reduction, interruption of treatment, or discontinuation. Discontinue TAVALISSE after 12 weeks of treatment if the platelet count does not increase to a level sufficient to avoid clinically important bleeding.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Hypertension: Monitor blood pressure every 2 weeks until stable, then monthly. Manage hypertension using standard antihypertensive treatment and, if needed, interrupt, reduce or discontinue TAVALISSE. Hepatotoxicity: Monitor LFTs monthly. If LFT levels are elevated, interrupt, reduce or discontinue TAVALISSE. Diarrhea: Manage diarrhea with supportive measures. If diarrhea becomes severe, interrupt, reduce or discontinue TAVALISSE. Neutropenia: Monitor ANC monthly, and for infection. If neutrophil count decreases below 1.0 × 10 9 /L, interrupt, reduce or discontinue TAVALISSE. Embryo-Fetal Toxicity: TAVALISSE can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.
Source: US FDA prescribing information
The following clinically important adverse reactions, that can become serious are described elsewhere in the labeling: Hypertension Hepatotoxicity Diarrhea Neutropenia The most common adverse reactions (≥5% and more than placebo) are diarrhea, hypertension, nausea, respiratory infection, dizziness, ALT/AST increased, rash, abdominal pain, fatigue, chest pain and neutropenia.
Source: US FDA prescribing information
Strong CYP3A4 Inhibitors: Concomitant use with a strong CYP3A4 inhibitor increases exposure to R406 (the major active metabolite). Strong CYP3A4 Inducers: Concomitant use is not recommended.
Source: US FDA prescribing information
Store at room temperature, 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Fostamatinib, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Tavalisse 100 mg tabletOral | Rigel Pharmaceuticals | US FDA | Available on request |
| Tavalisse 150 mg tabletOral | Rigel Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Fostamatinib in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Fostamatinib and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Fostamatinib, including Tavalisse.
Yes. The US FDA first approved Fostamatinib on 17 April 2018, according to Drugs@FDA.
Yes. Fostamatinib has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Fostamatinib is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Fostamatinib is classified under ATC code B02BX09 (Fostamatinib).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.